S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
S&P 500   3,363.00 (+0.83%)
DOW   27,781.70 (+1.20%)
QQQ   277.84 (+0.68%)
AAPL   115.81 (+1.51%)
MSFT   210.33 (+1.48%)
FB   261.90 (+0.04%)
GOOGL   1,465.60 (-0.03%)
AMZN   3,148.73 (+0.12%)
TSLA   429.01 (+2.37%)
NVDA   541.22 (+2.30%)
BABA   293.98 (+6.16%)
CGC   14.32 (-1.24%)
MU   46.96 (-7.39%)
GE   6.23 (+1.80%)
AMD   81.99 (+0.27%)
T   28.51 (+0.74%)
F   6.66 (+0.91%)
ACB   4.65 (-0.64%)
GILD   63.19 (+1.76%)
NFLX   500.03 (+1.33%)
DIS   124.08 (-1.05%)
BA   165.26 (+1.01%)
BAC   24.09 (+1.35%)
Log in
ASX:NOX

Noxopharm Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.19
MA: A$0.18
A$0.19
52-Week Range N/A
Volume1.23 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It is developing Veyonda, a dosage formulation of idronoxil, a generic anti-cancer agent for the treatment of late-stage cancers. The company also focuses on developing NYX-104, a drug intended to protect the brain from excitotoxicity; NYX-205, a drug to treat inflammation of the nervous tissue; and NYX-330, a PCSK9-inhibitor developed as a companion product for statin drugs in lowering low density lipoprotein cholesterol levels in patients at risk of cardiovascular disease. Noxopharm Limited was incorporated in 2015 and is based in Gordon, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.44 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9144 2223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.33 million
Book ValueA$0.06 per share

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive NOX News and Ratings via Email

Sign-up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Noxopharm (ASX:NOX) Frequently Asked Questions

How were Noxopharm's earnings last quarter?

Noxopharm Ltd (ASX:NOX) posted its quarterly earnings data on Thursday, February, 21st. The company reported ($0.04) earnings per share for the quarter.
View Noxopharm's earnings history
.

Who are some of Noxopharm's key competitors?

What other stocks do shareholders of Noxopharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Venture Minerals (VMS), Lincoln Educational Services (LINC) and IMMURON LTD/S (IMRN).

Who are Noxopharm's key executives?

Noxopharm's management team includes the following people:
  • Dr. Graham Edmund Kelly, Group CEO, MD & Director (Age 74)
  • Mr. David James Franks B.Ec, BEc, CA, F Fin, JP., Company Sec. (Age 49)
  • Dr. Greg van Wyk, CEO & Chief Medical Officer
  • Mr. Bhavin Raval, Chief Financial Officer
  • Dr. John Wilkinson, Chief Scientific Officer

What is Noxopharm's stock symbol?

Noxopharm trades on the ASX under the ticker symbol "NOX."

How big of a company is Noxopharm?

Noxopharm has a market capitalization of $0.00 and generates $8.33 million in revenue each year.

What is Noxopharm's official website?

The official website for Noxopharm is www.noxopharm.com.

How can I contact Noxopharm?

The company can be reached via phone at 61 2 9144 2223.

This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.